Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (931-940 of 962) with videos related to

Pageof 97
Sort By:
JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
JACC. Cardiovascular Interventions|April 9, 2016
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled AnalysisGennaro Giustino, Usman Baber, Melissa Aquino, et al.
Circulation. Cardiovascular Interventions|March 23, 2022
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China SubstudyYaling Han, Bimmer E Claessen, Shao-Liang Chen, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
JAMA|June 21, 2021
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 StatementAaron M Orkin, Peter J Gill, Davina Ghersi, et al.
European Heart Journal|March 11, 2026
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF modelTessa H Reitsma, Carl-Emil Lim, Mari N Gynnild, et al.
JACC. Cardiovascular Interventions|October 6, 2022
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass IndexVijay Kunadian, Usman Baber, Carlo A Pivato, et al.
JAMA|September 3, 2013
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialPhilippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
Annals of Internal Medicine|August 18, 2025
Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice GuidelinesMonica B Pagano, Simon J Stanworth, Jane Dennis, et al.
Pageof 97

Showing results (931-940 of 962) with videos related to

Sort By:
Pageof 97
JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
JACC. Cardiovascular Interventions|April 9, 2016
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled AnalysisGennaro Giustino, Usman Baber, Melissa Aquino, et al.
Circulation. Cardiovascular Interventions|March 23, 2022
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China SubstudyYaling Han, Bimmer E Claessen, Shao-Liang Chen, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
JAMA|June 21, 2021
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 StatementAaron M Orkin, Peter J Gill, Davina Ghersi, et al.
European Heart Journal|March 11, 2026
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF modelTessa H Reitsma, Carl-Emil Lim, Mari N Gynnild, et al.
JACC. Cardiovascular Interventions|October 6, 2022
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass IndexVijay Kunadian, Usman Baber, Carlo A Pivato, et al.
JAMA|September 3, 2013
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialPhilippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
Annals of Internal Medicine|August 18, 2025
Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice GuidelinesMonica B Pagano, Simon J Stanworth, Jane Dennis, et al.
Pageof 97